- Home
- HCI vs SNDX Comparison
HCI vs SNDX Comparison
Compare HCI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCI
- SNDX
- Stock Information
- Founded
- HCI 2006
- SNDX 2005
- Country
- HCI United States
- SNDX United States
- Employees
- HCI N/A
- SNDX N/A
- Industry
- HCI Property-Casualty Insurers
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- HCI Finance
- SNDX Health Care
- Exchange
- HCI Nasdaq
- SNDX Nasdaq
- Market Cap
- HCI 1.2B
- SNDX 1.4B
- IPO Year
- HCI N/A
- SNDX 2016
- Fundamental
- Price
- HCI $113.42
- SNDX $13.08
- Analyst Decision
- HCI Buy
- SNDX Strong Buy
- Analyst Count
- HCI 5
- SNDX 11
- Target Price
- HCI $140.00
- SNDX $37.64
- AVG Volume (30 Days)
- HCI 127.3K
- SNDX 2.2M
- Earning Date
- HCI 11-07-2024
- SNDX 11-05-2024
- Dividend Yield
- HCI 1.41%
- SNDX N/A
- EPS Growth
- HCI 163.93
- SNDX N/A
- EPS
- HCI 11.94
- SNDX N/A
- Revenue
- HCI $750,846,000.00
- SNDX $16,000,000.00
- Revenue This Year
- HCI N/A
- SNDX N/A
- Revenue Next Year
- HCI $7.38
- SNDX N/A
- P/E Ratio
- HCI $9.49
- SNDX N/A
- Revenue Growth
- HCI 48.73
- SNDX N/A
- 52 Week Low
- HCI $81.35
- SNDX $12.76
- 52 Week High
- HCI $126.50
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- HCI 49.25
- SNDX 28.91
- Support Level
- HCI $107.66
- SNDX $13.26
- Resistance Level
- HCI $113.51
- SNDX $14.18
- Average True Range (ATR)
- HCI 4.45
- SNDX 0.83
- MACD
- HCI -0.59
- SNDX -0.18
- Stochastic Oscillator
- HCI 36.24
- SNDX 7.08
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are HCPCI insurance operations, TypTap Group, Real estate operations, and Corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.